Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Ordinary shares, nominal value 0.002 GBP per share
-
Shares outstanding
-
145,993,531
-
Total 13F shares
-
52,983,439
-
Share change
-
+9,505,365
-
Total reported value
-
$881,813,000
-
Price per share
-
$16.70
-
Number of holders
-
38
-
Value change
-
+$147,088,157
-
Number of buys
-
18
-
Number of sells
-
29
Institutional Holders of Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (CNTA) as of Q3 2021
As of 30 Sep 2021,
Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (CNTA) was held by
38 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
52,983,439 shares.
The largest 10 holders included
Medicxi Ventures Management (Jersey) Ltd, GENERAL ATLANTIC, L.P., JANUS HENDERSON GROUP PLC, RA CAPITAL MANAGEMENT, L.P., PRICE T ROWE ASSOCIATES INC /MD/, Cormorant Asset Management, LP, Samsara BioCapital, LLC, BOXER CAPITAL, LLC, BAKER BROS. ADVISORS LP, and VR Adviser, LLC.
This page lists
38
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.